tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate | 1235141-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate
• 英文别名: tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 1235141-58-8
• 化学式: C₂₀H₃₀BNO₄
• 分子量: 359.273
• InChiKey: MZVRKOQBGRBLIS-UHFFFAOYSA-N

物化性质

• 沸点：
  461.2±44.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.67
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.58h， 生成 6-(1,2,3,4-tetrahydroquinolin-7-yl)picolinic acid
  参考文献：
  名称：

  Structure-Guided Rescaffolding of Selective Antagonists of BCL-X_L

  摘要：

  Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-X-L antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.

  DOI：

  10.1021/ml500030p
• 作为产物：
  描述：

  6-溴茚酮 在 4-二甲氨基吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 lithium aluminium tetrahydride 、 盐酸羟胺 、 potassium acetate 、 甲基磺酰氯 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 5.58h， 生成 tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate
  参考文献：
  名称：

  Structure-Guided Rescaffolding of Selective Antagonists of BCL-X_L

  摘要：

  Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-X-L antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.

  DOI：

  10.1021/ml500030p

文献信息

• [EN] PURINES AND METHODS OF THEIR USE<br/>[FR] PURINES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：YUMANITY THERAPEUTICS INC

  公开号：WO2021247841A1

  公开（公告）日：2021-12-09

  Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

  本文披露了在治疗神经系统疾病中有用的化合物。这些化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• COMPOUNDS AND METHODS OF USE
  申请人：Baell Jonathan Bayldon

  公开号：US20120184541A1

  公开（公告）日：2012-07-19

  In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X 1 , X 2a , X 2b , X 2c , R 1 , B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-x L proteins.

  在一个方面，本发明提供了一种公式I的化合物，其中在公式I中，变量X1、X2a、X2b、X2c、R1、B、L、E、A和下标n的定义如本文所述。在另一个方面，本发明提供了包含公式I化合物的药物组合物，以及使用公式I化合物治疗通过表达或过度表达Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的疾病和病况（例如癌症、血小板增多症等）的方法。
• Compounds and methods of use
  申请人：Baell Jonathan Bayldon

  公开号：US08518970B2

  公开（公告）日：2013-08-27

  In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

  在一个方面，本发明提供了一个式子为I的化合物，其中在式子I中，变量X1、X2a、X2b、X2c、R1、B、L、E、A和下标n的定义如本文所述。在另一个方面，本发明提供了包括式子I化合物的制药组合物，以及使用式子I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过度表达所特征的疾病和病况（例如癌症、血小板增多症等）的方法。
• WO2024006379A1
  申请人：——

  公开号：——

  公开（公告）日：——